This process reduces the transcriptional expression of downstream lipid metabolism-related genes, including ACC1 and FASN. Therefore, the FA de novo synthesis process is modulated, and the progression of HCC is inhibited. The gene discussed is FASN; the disease is hepatocellular carcinoma.